Evidence mapPaperPMID 36298592Full record

ReviewVaccines2022

Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review.

Navami Prabhakar Koyande, Rupali Srivastava, Ananya Padmakumar, Aravind Kumar Rengan

Abstract readReview
In one paragraph

Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Condensate nanovaccine adjuvants augment CD8Signal transduction and targeted therapy · 2025
    Article
  4. Review
  5. Review
  6. Application of nanomedicines in tumor immunotherapy.Journal of molecular cell biology · 2025
    Review
  7. RSC advances · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. A Review of Immunotherapy for Head and Neck Cancer.Journal of dental research · 2024
    Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Navami Prabhakar KoyandeDepartment of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, Sangareddy 502285, India.ORCID 0000-0001-8641-7680
Rupali SrivastavaDepartment of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, Sangareddy 502285, India.ORCID 0000-0002-9351-5622
Ananya PadmakumarDepartment of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, Sangareddy 502285, India.ORCID 0000-0001-5908-7786
Aravind Kumar RenganDepartment of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, Sangareddy 502285, India.ORCID 0000-0003-3994-6760

Funding

Department of Biotechnology (Government of India) DBT/CE/F064/2020- 534 21/G307
6 · The paper itself

Abstract

One of the most effective cancer therapies, cancer immunotherapy has produced outstanding outcomes in the field of cancer treatment. However, the cost is excessive, which limits its applicability. A smart way to address this issue would be to apply the knowledge gained through immunotherapy to develop strategies for the immunoprevention of cancer. The use of cancer vaccines is one of the most popular methods of immunoprevention. This paper reviews the technologies and processes that support the advantages of cancer immunoprevention over traditional cancer immunotherapies. Nanoparticle drug delivery systems and nanoparticle-based nano-vaccines have been employed in the past for cancer immunotherapy. This paper outlines numerous immunoprevention strategies and how nanotechnology can be applied in immunoprevention. To comprehend the non-clinical and clinical evaluation of these cancer vaccines through clinical studies is essential for acceptance of the vaccines.

Indexed as

cancer immunotherapycancer vaccinesclinical trialsimmunomodulationtumor antigens

Identifiers

PMID36298592
PMCPMC9610880

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.